作者机构：
[Wang, Jikai; Zeng, Pengfei; Xiao, Xilin; Zhou, Cheng; Wei, Hua; Yu, Cuiyun] Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy & Pharmacology, Hengyang Medical School, University of South China, Hunan, Hengyang;421001, China;[Wang, Jikai; Zeng, Pengfei; Xiao, Xilin; Zhou, Cheng; Wei, Hua; Yu, Cuiyun] 421001, China
通讯机构：
[Jikai Wang; Hua Wei; Cuiyun Yu] H;Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy & Pharmacology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People's Republic of China
作者机构：
[Zhou, Jing; Yao, Xu; Xiang, Yi-Jun; Liu, Shun] Univ South China, Inst Pharm & Pharmacol, Hunan Prov Key Lab Tumor Microenvironm Respons Dru, Hengyang 421001, Peoples R China.;[Lin, Jin-Hong; Xiao, Ji-Chang; Xiang, Yi-Jun] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Organ Chem, Key Lab Organofluorine Chem, Shanghai 200032, Peoples R China.;[Lin, Jin-Hong] Shanghai Univ, Innovat Drug Res Ctr, Dept Chem, Shanghai 200444, Peoples R China.
通讯机构：
[Jin-Hong Lin; Ji-Chang Xiao] K;[Xu Yao] I;Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, 421001 Hengyang, PR China<&wdkj&>Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 345 Lingling Road, 200032 Shanghai, PR China<&wdkj&>Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 345 Lingling Road, 200032 Shanghai, PR China<&wdkj&>Department of Chemistry, Innovative Drug Research Center, Shanghai University, 200444 Shanghai, PR China
作者机构：
[Li, Ao; He, Longwei; Liu, Yalan; Chen, Zhe; Li, Songjiao; Chen, Linxi] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dru, Sch Pharm, Hengyang Med Sch,Hunan Prov Key Lab Tumor Microen, Hengyang 421001, Peoples R China.;[Zhong, Rongbin; Cheng, Dan] Univ South China, Affiliated Nanhua Hosp, Clin Res Inst, Hengyang Med Sch, Hengyang 421002, Peoples R China.
通讯机构：
[Linxi Chen; Longwei He] S;School of Pharmacy, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang Medical School, University of South China, Hengyang, 421001, PR China
作者机构：
[Liu, Ying; Yang, Ke; He, Longwei; Wang, Peipei; Li, Songjiao] Univ South China, Hengyang Med Sch, Canc Res Inst, Hunan Prov Cooperat Innovat Ctr Mol Target New Dru, Hengyang 421001, Peoples R China.;[Cheng, Dan] Univ South China, Affiliated Nanhua Hosp, Hengyang Med Sch, Clin Res Inst, Hengyang, Peoples R China.
通讯机构：
[Dan Cheng] C;[Longwei He] H;Clinical Research Institute, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China<&wdkj&>Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Cancer Research Institute, Department of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, PR China
作者机构：
[Ding, Yiteng; Zhong, Rongbin; Yang, Xuefeng; Cheng, Dan] Univ South China, Affiliated Nanhua Hosp, Clin Res Inst, Hunan Prov Clin Res Ctr Metab Associated Fatty Liv, Hengyang 421002, Hunan, Peoples R China.;[He, Longwei; Jiang, Renfeng] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dru, Hengyang Med Sch, Dept Pharm & Pharmacol, Hengyang 421002, Hunan, Peoples R China.;[Yuan, Lin; He, Longwei; Cheng, Dan] Hunan Univ, Coll Chem & Chem Engn, State Key Lab Chemo Biosensing & Chemometr, Changsha 410082, Peoples R China.
通讯机构：
[Longwei He; Dan Cheng] H;Hunan Provincial Clinical Research Center for Metabolic Associated Fatty Liver Disease, Clinical Research Institute, the Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang 421002, Hunan, China<&wdkj&>State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, P. R. China<&wdkj&>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Department of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang 421002, Hunan, China<&wdkj&>State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, P. R. China
关键词：
near-infrared;fluorescent probe;reversible imaging;peroxynitrite and glutathione;acute kidney injury
通讯机构：
[Zhiqiang Mao] C;[Longwei He] H;College of Health Science and Engineering, Hubei University, Wuhan 430062, China<&wdkj&>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Department of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang 421002, China
作者机构：
[Liu, Ying; Yang, Ke; He, Longwei; Wang, Peipei; Li, Songjiao] Univ South China, Canc Res Inst, Hunan Prov Cooperat Innovat Ctr Mol Target New Dru, Hengyang Med Sch,Hunan Prov Key Lab Tumor Microenv, Hengyang 421001, Peoples R China.;[Zhong, Rongbin; Cheng, Dan] Univ South China, Affiliated Nanhua Hosp, Clin Res Inst, Hengyang Med Sch, Hengyang 421001, Peoples R China.
通讯机构：
[Dan Cheng] C;[Longwei He] H;Clinical Research Institute, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, PR China<&wdkj&>Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Cancer Research Institute, Department of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, PR China
作者机构：
[Zeng, Jiayu; Yuan, Lin; Zhong, Rongbin; He, Longwei; Yang, Xuefeng; Cheng, Dan; Jiang, Renfeng] Univ South China, Affiliated Nanhua Hosp, Clin Res Inst,Hengyang Med Sch, Hunan Prov Clin Res Ctr Metab Assoc Fatty Liver Di, Hengyang 421002, Hunan, Peoples R China.;[Yuan, Lin; Gong, Xiangyang; Cheng, Dan] Hunan Univ, Coll Chem & Chem Engn, State Key Lab Chemo Biosensing & Chemomet, Changsha 410082, Peoples R China.
通讯机构：
[Longwei He; Dan Cheng] H;Hunan Provincial Clinical Research Center for Metabolic Associated Fatty Liver Disease, Clinical Research Institute, the Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, 421002 Hunan, China<&wdkj&>State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, 410082 Changsha, P. R. China<&wdkj&>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Department of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421002 Hunan, China
作者机构：
[Wang, Weiguo; Yang, ZeHua; Yang, Lin; He, Jian; Cao, Qianqian; Zhang, Ruilin] Univ South China, Inst Pharm & Pharmacol, Hengyang 421000, Hunan, Peoples R China.;[Wang, Weiguo; Yang, ZeHua; Yang, Lin; He, Jian; Cao, Qianqian; Zhang, Ruilin] Hunan Xinhexin Biol Med Co Ltd, Pharm Grad Educ Innovat Base, Hunan Prov Cooperat Innovat Ctr Mol Target New Dru, Hengyang 421000, Hunan, Peoples R China.;[Wang, Qiao] Univ South China, Affiliated Hosp 1, Dept Ultrasound Imaging, Hengyang Med Coll, Hengyang 421001, Hunan, Peoples R China.;[Chen, Zhixi] Univ South China, Affiliated Hosp 1, Hengyang Med Coll, Blood Transfus Dept, Hengyang 421001, Hunan, Peoples R China.;[Chen, Weiwei] Univ South China, Hengyang Med Coll, Hengyang 421000, Hunan, Peoples R China.
通讯机构：
[Weiguo Wang] I;Institute of Pharmacy and Pharmacology, University of South China, Hengyang 421000, Hunan, China<&wdkj&>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang 421000, Hunan, China<&wdkj&>Hunan Xinhexin Biological Medicine Co., Ltd., Pharmacy Graduate Education Innovation Base, Hengyang 421000, Hunan, China
作者机构：
[He, LW; Zeng, Jiayu; Yang, Ke; He, Longwei; Li, Songjiao] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang Med Sch, Canc Res Inst,Dept Pharm & Pharmacol, Hengyang, Peoples R China.;[Cheng, Dan; Xia, Yuqing] Univ South China, Affiliated Nanhua Hosp, Hengyang Med Sch, Clin Res Inst, Hengyang, Peoples R China.;[Cheng, Dan] Hunan Univ, Coll Chem & Chem Engn, State Key Lab Chemo Biosensing & Chemometr, Changsha, Peoples R China.
通讯机构：
[He, LW ; Cheng, D ] U;Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang Med Sch, Canc Res Inst,Dept Pharm & Pharmacol, Hengyang, Peoples R China.;Univ South China, Affiliated Nanhua Hosp, Hengyang Med Sch, Clin Res Inst, Hengyang, Peoples R China.;Hunan Univ, Coll Chem & Chem Engn, State Key Lab Chemo Biosensing & Chemometr, Changsha, Peoples R China.
摘要：
Carbon monoxide (CO) is regarded as one of the most important gaseous transmitters, playing a vital role in biological systems; meanwhile, abnormal levels of CO can be correlated with conditions such as lung disease, Alzheimer's disease, and cardiovascular disease. CO-releasing molecules (CORMs) are chemical agents used to release CO as an endogenous, biologically active molecule in order to treat diseases. CO-releasing molecule-3 (CORM-3), as a convenient and safe CO donor and therapeutic drug molecule, has been widely used to release exogenous CO in living cells to study the physiological and pathological roles of CO in living systems. Herein, we designed a NIR-emitting probe (NIR-CORM-3) with a large Stokes shift based on a 4-(dimethylamino)cinnamaldehyde lepidine derived fluorophore. A 4-nitrobenzyl group was selected as the CORM-3 recognizing moiety, and the probe is able to selectively and sensitively respond to CORM-3 (within only 15 min). Upon encountering CORM-3, NIR-CORM-3 releases a fluorophore with a response at 670 nm, and it shows a remarkable Stokes shift (up to 250 nm). In addition, NIR-CORM-3 has low cytotoxicity and exhibits outstanding NIR imaging abilities in living cells and mice.
作者机构：
[Zhang, Miao; Wei, Hua; Ma, Liwei; Liu, Fangjun] Lanzhou Univ, Key Lab Nonferrous Met Chem & Resources Utilizat, State Key Lab Appl Organ Chem, Lanzhou 730000, Gansu, Peoples R China.;[Zhang, Miao; Wei, Hua; Ma, Liwei; Liu, Fangjun] Lanzhou Univ, Coll Chem & Chem Engn, Lanzhou 730000, Gansu, Peoples R China.;[Wei, Hua; Wang, Dun; Yu, Cui-Yun] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang 421001, Peoples R China.;[Wei, Hua; Wang, Dun; Yu, Cui-Yun] Univ South China, Dept Pharm & Pharmacol, Hengyang 421001, Peoples R China.
通讯机构：
[Liwei Ma; Hua Wei] S;[Cui-Yun Yu] H;State Key Laboratory of Applied Organic Chemistry, Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, and College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, Gansu 730000, China<&wdkj&>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study & Department of Pharmacy and Pharmacology, University of South China, Hengyang, 421001, China<&wdkj&>State Key Laboratory of Applied Organic Chemistry, Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, and College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, Gansu 730000, China<&wdkj&>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study & Department of Pharmacy and Pharmacology, University of South China, Hengyang, 421001, China
关键词：
Anticancer drug delivery;Cell imaging;Conjugated bottlebrush copolymers;Enzyme-responsive;Theranostic micelles
作者机构：
[Zhu, Yanli] Hunan Univ Technol & Business, Sch Resources & Environm, Changsha 410205, Peoples R China.;[Zhou, Jiecan; Xie, Haitao; Fu, Chengxiao] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Clin Lab,Hengyang Clin Pharmacol Res Ctr, Hengyang 421001, Peoples R China.;[Liu, Hailing] Wuhan Univ, Dept Respirator y & Crit Care Med, Renmin Hosp, Wuhan 430060, Peoples R China.;[Wang, Jikai; Sun, Yiyang; Zeng, Pengfei] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dru, Inst Pharm & Pharmacol, Hengyang Med Sch, Hengyang 421001, Hunan, Peoples R China.
通讯机构：
[Jikai Wang] H;Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy & Pharmacology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P. R. China
通讯机构：
[Zheng, Z.] H;[Chen, S.; Jiang, Z.-X.] S;Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan, China;State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, China
摘要：
<jats:p>As a noninvasive “hot-spot” imaging technology, fluorine-19 magnetic resonance imaging (<jats:sup>19</jats:sup>F MRI) has been extensively used in cell tracking. However, the peculiar physicochemical properties of perfluorocarbons (PFCs), the most commonly used <jats:sup>19</jats:sup>F MRI agents, sometimes cause low sensitivity, poor cell uptake, and misleading results. In this study, a partially fluorinated agent, perfluoro-<jats:italic>tert</jats:italic>-butyl benzyl ether, was used to formulate a <jats:sup>19</jats:sup>F MRI-fluorescence imaging (FLI) dual-modal nanoemulsion for cell tracking. Compared with PFCs, the partially fluorinated agent showed considerably improved physicochemical properties, such as lower density, shorter longitudinal relaxation times, and higher solubility to fluorophores, while maintaining high <jats:sup>19</jats:sup>F MRI sensitivity. After being formulated into stable, monodisperse, and paramagnetic Fe<jats:sup>3+</jats:sup>-promoted nanoemulsions, the partially fluorinated agent was used in <jats:sup>19</jats:sup>F MRI-FLI dual imaging tracking of lung cancer A549 cells and macrophages in an inflammation mouse model.</jats:p>
作者机构：
[Liu, Ying; Wang, Weiguo; Yang, Lin; He, Jian; He, Dongxiu; Tian, Jinming] Univ South China, Inst Pharm & Pharmacol, Hengyang 421000, Hunan, Peoples R China.;[Liu, Ying; Wang, Weiguo; Yang, Lin; He, Jian; He, Dongxiu; Tian, Jinming] Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang, Hunan, Peoples R China.;[Liu, Ying; Wang, Weiguo; Yang, Lin; He, Jian; He, Dongxiu; Tian, Jinming] Hunan Xinhexin Biol Med Co Ltd, Pharm Grad Educ Innovat Base, Hengyang, Hunan, Peoples R China.;[Wu, Gui-Long] Univ South China, Med Instrument & Equipment Technol Lab, Hengyang Med Coll, Hengyang 421000, Hunan, Peoples R China.
通讯机构：
[Wang, WG ] U;Univ South China, Inst Pharm & Pharmacol, Hengyang 421000, Hunan, Peoples R China.;Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang, Hunan, Peoples R China.;Hunan Xinhexin Biol Med Co Ltd, Pharm Grad Educ Innovat Base, Hengyang, Hunan, Peoples R China.
摘要：
<jats:title>Abstract</jats:title><jats:p>Natural killer (NK) cell‐based immunotherapy holds prominent potential for cancer treatment. However, its application in solid tumors is limited by a rapid decline in viability and function, as well as inadequate homing and infiltration. Herein, a generalized strategy is offered to construct a bio‐orthogonal targeted live‐cell nanocarrier (N<jats:sub>3</jats:sub>‐NK‐NPs) by coupling with responsive released interleukin‐21 (IL‐21) nanoparticles (ILNPs) on glyco‐engineered NK cell surfaces. Complementary bio‐orthogonal groups (azide (N<jats:sub>3</jats:sub>)/bicyclo [6.1.0] nonyne (BCN), serving as an artificial ligand receptor are separately implanted into NK cells (N<jats:sub>3</jats:sub>‐NK) and tumor cells (BCN‐Raji) via nondestructive metabolic glycoengineering. The bio‐orthogonal strategy effectively promotes the specific recognition and migration of NK cells, showing nearly fourfold deeper infiltration in tumor than control groups. Compared with traditional systemic administration, ILNPs hitchhiking on cell vectors selectively in situ releases the IL‐21 adjuvant in the tumor to produce effective and continuous “pseudo‐autocrine” stimulation surrounding NK cells under a low dose (5µgkg<jats:sup>–1</jats:sup>), which greatly promotes proliferation and activation of NK cells, resulting in enhanced therapeutic potential while limiting systemic toxicity. Importantly, live‐cell nanocarrier effectively activates innate immune system through IL‐21 triggered recruitment of multiple immunocytes, significantly improving tumor immune microenvironment. This in situ activated NK cell nanocarrier with bio‐orthogonal targeting provides a universal and powerful strategy for immune cells activation and solid tumor immunotherapy.</jats:p>
